Venetoclax Combined with Hypomethylating Agents for Treatment-Naïve B/Myeloid Mixed Phenotype Acute Leukemia

Mixed phenotype acute leukemia (MPAL) is a rare hematological malignancy that lacks consensus on optimal management. We report for the first time two cases of treatment-naïve B/myeloid MPAL patients treated with a novel chemo-free regimen using venetoclax combined with hypomethylating agents, which...

Full description

Saved in:
Bibliographic Details
Main Authors: Di Wu, Wenlan Chen, Zhichao Chen, Qiubai Li
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:Case Reports in Hematology
Online Access:http://dx.doi.org/10.1155/2021/6661109
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849306531133128704
author Di Wu
Wenlan Chen
Zhichao Chen
Qiubai Li
author_facet Di Wu
Wenlan Chen
Zhichao Chen
Qiubai Li
author_sort Di Wu
collection DOAJ
description Mixed phenotype acute leukemia (MPAL) is a rare hematological malignancy that lacks consensus on optimal management. We report for the first time two cases of treatment-naïve B/myeloid MPAL patients treated with a novel chemo-free regimen using venetoclax combined with hypomethylating agents, which successfully induced complete remission with tolerable toxicities.
format Article
id doaj-art-2d3295ab12184d84a8c9142d0ff7e486
institution Kabale University
issn 2090-6560
2090-6579
language English
publishDate 2021-01-01
publisher Wiley
record_format Article
series Case Reports in Hematology
spelling doaj-art-2d3295ab12184d84a8c9142d0ff7e4862025-08-20T03:55:02ZengWileyCase Reports in Hematology2090-65602090-65792021-01-01202110.1155/2021/66611096661109Venetoclax Combined with Hypomethylating Agents for Treatment-Naïve B/Myeloid Mixed Phenotype Acute LeukemiaDi Wu0Wenlan Chen1Zhichao Chen2Qiubai Li3Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei, ChinaInstitute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei, ChinaInstitute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei, ChinaInstitute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei, ChinaMixed phenotype acute leukemia (MPAL) is a rare hematological malignancy that lacks consensus on optimal management. We report for the first time two cases of treatment-naïve B/myeloid MPAL patients treated with a novel chemo-free regimen using venetoclax combined with hypomethylating agents, which successfully induced complete remission with tolerable toxicities.http://dx.doi.org/10.1155/2021/6661109
spellingShingle Di Wu
Wenlan Chen
Zhichao Chen
Qiubai Li
Venetoclax Combined with Hypomethylating Agents for Treatment-Naïve B/Myeloid Mixed Phenotype Acute Leukemia
Case Reports in Hematology
title Venetoclax Combined with Hypomethylating Agents for Treatment-Naïve B/Myeloid Mixed Phenotype Acute Leukemia
title_full Venetoclax Combined with Hypomethylating Agents for Treatment-Naïve B/Myeloid Mixed Phenotype Acute Leukemia
title_fullStr Venetoclax Combined with Hypomethylating Agents for Treatment-Naïve B/Myeloid Mixed Phenotype Acute Leukemia
title_full_unstemmed Venetoclax Combined with Hypomethylating Agents for Treatment-Naïve B/Myeloid Mixed Phenotype Acute Leukemia
title_short Venetoclax Combined with Hypomethylating Agents for Treatment-Naïve B/Myeloid Mixed Phenotype Acute Leukemia
title_sort venetoclax combined with hypomethylating agents for treatment naive b myeloid mixed phenotype acute leukemia
url http://dx.doi.org/10.1155/2021/6661109
work_keys_str_mv AT diwu venetoclaxcombinedwithhypomethylatingagentsfortreatmentnaivebmyeloidmixedphenotypeacuteleukemia
AT wenlanchen venetoclaxcombinedwithhypomethylatingagentsfortreatmentnaivebmyeloidmixedphenotypeacuteleukemia
AT zhichaochen venetoclaxcombinedwithhypomethylatingagentsfortreatmentnaivebmyeloidmixedphenotypeacuteleukemia
AT qiubaili venetoclaxcombinedwithhypomethylatingagentsfortreatmentnaivebmyeloidmixedphenotypeacuteleukemia